Nicotine and nicotinic receptor involvement in neuropsychiatric disorders

Current Topics in Medicinal Chemistry

Volumn 4, Issue 3, 2004, Pages 267-282

  Newhouse, Paul ^a   Singh, Abhay ^a   Potter, Alexandra ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE FUMARATE; ALPRAZOLAM; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; BUSPIRONE; CLONIDINE; CLOZAPINE; DIAZEPAM; DONEPEZIL; DOPAMINE; DOXEPIN; GALANTAMINE; HALOPERIDOL; HYDROXYZINE; LEVODOPA; MECAMYLAMINE; MEPROBAMATE; NICOTINE; NICOTINE GUM; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORTRIPTYLINE; RECEPTOR SUBTYPE; RIVASTIGMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TACRINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; BRAIN METABOLISM; CIGARETTE SMOKING; COGNITION; DEGENERATIVE DISEASE; DOPAMINE RELEASE; DROWSINESS; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EVOKED AUDITORY RESPONSE; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MENTAL DISEASE; MOOD DISORDER; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; REM SLEEP; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; SMOOTH PURSUIT EYE MOVEMENT; SUBSTANTIA NIGRA; TARDIVE DYSKINESIA; TASK PERFORMANCE; XEROSTOMIA; CENTRAL NERVOUS SYSTEM DISEASE; PHYSIOLOGY;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MENTAL DISORDERS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC;

EID: 1642381382     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451401     Document Type: Review

References (244)

1. Abel, L.; Friedman, L.; Jesberger, J.; Malki, A.; Melzer, H. Y. Quantitative assessment of smooth pursuit gain and catch-up saccades in schizophrenia and affective disorders. Biological. Psychiatry 1991, 29, 1063-1072.
2. Abel, L. A.; Hertle, R.W. Effects of psychoactive drugs on ocular motor behavior. In Johnston, CW, Pirozzolo, FJ, editors. Neuropsychology of Eye Movements. Hillsdale, New Jersey: Lawrence Erlbaum Associates 1988, pp 81-114.
3. Adler, L. E.; Hoffer, L. D.; Wiser, A.; Freedman, R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 1993, 150, 1856-1861.
4. Adler, L. E.; Olincy, A.; Waldo, M.; Harris, J. G.; Griffith, J.; Stevens, Flach K.; Nagamoto, H.; Bickford, P.; Leonard, S.; Freedman, R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bull 1998, 24, 189-202.
5. Adler, L. E.; Hoffer, L. D.; Wiser, A.; Freedman, R.: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 1993, 150, 1856-1861.
6. Akaike, A.; Tamura, Y.; Yokota, T.; Shimohama, S.; and Kimura, J. Nicotine-induced protection of cultured cortical neurons against N-Methyl-D-Aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 1994, 644, 181-187.
7. Allgower, A.; Wardle, J.; Steptoe, A. Depressive symptoms, social support, and personal health behavior in young men and women. Health Psychology 2001, 20, 233-237.
8. Anda, R. F.; Williamson, D.F.; Escobedo, L. G. Depression and the dynamics of smoking: a national perspective. Journal of American Medical Association 1990, 264, 1541-1545.
9. Andersson, K.; Fuxe, K.; Agnati, L. F. Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Acta. Physiologica. Scandinavica 1981, 112, 345-347.
10. Aubert, I.; Araujo, D. M.; Cecyre, D.; Robitaille, Y.; Gauthier, S.; Quirion, R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. Journal of Neurochemistry 1992, 58, 529-541.
11. Barkley, R. A. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychological Bulletin 1997, 121, 65-94.
12. Baron, J. A. Epidemiology of smoking and Parkinson's disease. In Clarke, QTA, editor. Effects of Nicotine on Biological Systems II. Boston: Birkhäuser 1994, p S42.
13. Baron, J. Cigarette smoking and Parkinson's disease. Neurology 1986, 36, 1490-1496.
14. Baumann, R.; Jameson, H.; McKean, H. Cigarette smoking and Parkinson's disease: 1. Comparison of cases with matched neighbors. Neurology 1980, 30, 839-843.
15. Bejerot, S.; Humble, M. Low prevalence of smoking among patients with obsessive-compulsive disorder. Comprehensive Psychiatry 1999, 40, 268-272.
16. Benwell, M. E. M.; Balfour, D. J. K. Regional variation in the effects of nicotine on catecholamine overflow in rat brain. European Journal of Pharmacology 1997, 325, 13-20.
17. Berlin, I.; Said, S.; Spreux-Varoquaux, O.; Launay, J. M.; Olivares, R.; Millet, V.; Lecrubier, Y.; Puech, A. J.; A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clinical and Pharmacological Therapeutics 1995, 58, 444.
18. Bickford, P. C.; Wear, K. D. Restoration of sensory gating of auditory evoked response by nicotine in fimbria-fornix lesioned rats. Brain Res 1995, 705, 235-240.
19. Brenner, D.E.; Kukull, W. A.; vanbelle, G.; Bowen, J. D.; Mccormick, W. C.; Teri, L.; Larson, E. B. Relationship between cigarette smoking and Alzheimer's Disease in a population-based case-control study. Neurology 1993, 43, 293-300.
20. Breslau, N.; Kilbey, M.; Andreski, P. Nicotine dependence, major depression, and anxiety in young adults. Archives of General Psychiatry 1991 48, 1069-74.
21. Breslau, N.; Kilbey, M.M.; Andreski, P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiological study of young adults. American Journal of Psychiatry 1992, 149, 464.
22. Breslau, N.; Kilbey, M.M.; Andreski, P. Nicotine dependence and major depression: new evidence from a prospective investigation. Archives of General Psychiatry 1993, 50, 31-35.
23. Breslau, N.; Klein, D.F. Smoking and panic attacks-an epidemiologic investigation. Archives of General Psychiatry 1999, 56, 1141-1147.
24. Brioni, J.D.; O'Neill, A.B.; Kim, D.J.; Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. European Journal of Pharmacology 1993, 238, 1-8.
25. Brooks, J.S.; Whiteman, M.; Czeisler, L.J.; Shapiro, Cohen, P. Cigarette smoking in young adults: childhood and adolescent personality, familial, and peer antecedents. Journal of Genetic Psychology 1997, 158, 172-188.
26. Brown, R.A.; Kahler, C.W.; Zvolensky, M.J.; Lejuez, C.W.; Ramsey, S.E. Anxiety sensitivity: Relationship to negative affect smoking and smoking cessation in smokers with past major depressive disorder. Addictive Behaviors 2001, 26, 887-899.
27. Cadenhead, K.S.; Geyer, M.A.; Braff, D.L. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. American Journal of Psychiatry 1993, 150, 1862-1867.
28. Cinciripini, P.M.; Laptizky, L.; Seay, S.; Walfisch, A.; Meyer, W.J.; Van vanakis, H.A. Placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high-and low-anxiety smokers. Journal of Clinical Psychopharmacology 1995, 15, 182-191.
29. Clarke, P.B.; Reuben, M. Release of [3H]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release. British Journal of Pharmacology 1996, 117, 595-606.
30. Clemens, P.; Baron, J.A.; Coffey, D.; Reeves, A. The short-term effect of nicotine chewing gum in patients with Parkinson's disease. Psychopharmacology 1995, 117, 253-256.
31. Clementz, B.A.; Grove W.M.; Jacono, W.G.; Sweeny, J.A. Smooth-pursuit eye movement dysfunction and liability for schizophrenia: implications for genetic modeling. Journal of Abnormal Psychology 1992, 101, 117-129.
32. Colquhoun, L.M.; Patrick, J.W. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Advances in Pharmacology 1997, 39, 191-220.
33. Covey, L. S.; Glassman, A. H.; Stetner, F. Depression and depressive symptoms in smoking cessation. Comprehensive Psychiatry 1990, 31, 350-354.
34. Covey, L.S.; Glassman, A.H.; Stetner, F. Major depression following smoking cessation. American Journal of Psychiatry 1997, 154, 263.
35. Covey, L.S.; Hughes, D.C.; Glassman, A.H.; Blazer, D.G.; George, L.K. Ever smoking, quitting, and psychiatric disorders: Evidence from Durham, North Carolina, Epidemiologic Catchment Area. Tobacco Control 1994, 3, 222-227.
36. Dalack, G.W.; Becks, L.; Hill, E.; Pomerleau, O.; Meador-Woodruff, J.H. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999, 21, 195-202.
37. Dalack, G.W.; Healy, D.J.; Meador-Woodruff, J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. American Journal of Psychiatry 1998, 155, 1490-501.
38. Dalack, G.W.; Meador-Woodruff, J.H. Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophrenia Research 1996, 22, 133-141.
39. Dalack, G.W.; Meador-Woodruff, J.H. Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine and Tobacco Research 1999, 1, 53-57.
40. Dani, J.A. Overview of nicotinic receptors and their roles in the central nervous system. Biological Psychiatry 2001, 49, 166-174.
41. Dawe, S.; Gerada, C.; Russel, M.A.H.; Gray, J.A. Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl) 1995, 117, 110-115.
42. Dineley, K.T.; Westerman, M.; Bui, D.; Bell, K.; Ashe, K.H.; Sweatt, J.D. βAmyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. Journal of Neuroscience 2001, 21, 4125-4133.
43. Diwan, A.; Castine, M.; Pomerleau, C.S.; Meador-Woodruff, J.H.; Dalack, G.W. Differential prevalence of cigarette smoking in patients with schizophrenia Vs mood disorders. Schizophrenia Research 1998, 33, 113-118.
44. Domino, E.F. Tobacco smoking and nicotine neuropsychopharmacology: Some future research directions. Neuropsychopharmacology 1998, 18, 456-468.
45. Douglas, V.I. Attention and cognitive problems. In Rutter M.; editor. Developmental Neuropsychiatry. New York: 1983 Guilford Press, pp 280-329.
46. Dow, R.J.; Fee, W.M. Use of beta-blocking agents with group therapy in a smoking withdrawal clinic. Journal of the Royal Society of Medicine 1984, 77, 648-651.
47. Dubois, B.; Danze, F.; Pillon, B.; Cusimano, G.; Lhermitte, F.; Agid, Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Annals of Neurology 1987, 22, 26-30.
48. Dursan, S.; Revely, M.; Bord, R. Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet 1994, 344, 1577.
49. Edwards, N.B.; Murphy, J.K.; Downs, A.D.; Ackerman, B.J.; Rosenthal, T.L. Doxepine as an adjunct to smoking cessation: a double blind pilot study. American Journal of Psychiatry 1989, 146, 373-376.
50. Emerich, D.F.; Zanol, M.D.; Norman, A.B.; McConville, B.J.; Sanberg, P.R. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity. Pharmacology Biochemistry and Behavior 1991, 38, 875-880.
51. Ereshefsky, L.; Jann, M.W.; Saklad, S.R.; Davis, C.M.; Richards, A.L.; Burch, N.R. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biological Psychiatry 1985, 20, 329-332.
52. Fagerström, K. O.; Pomerleau, O.; Giordani, B.; and Stelson, F. Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 1994, 116, 117-119.
53. Fan, H.; Scheffel, U.A.; Rauseo, P.; Xiao, Y.; Dogan, A.S.; Yokoi, F. et al Structure-in vivo activity of [I-125/123] 5-iodo-3-pyridyl ethers as potential nicotinic acetylcholine receptor tracers. Nuclear Medicine & Biology 2001, 28, 911-921.
54. Farebrother, M.J.B.; Pearce S.J.; Turner, P.; Appleton, D.R. Propranolol and giving up smoking. British Journal of Diseases of the Chest 1980, 74, 95-96.
55. File, S.E.; Cheeta, S.; Kenny, P.J. Neurobiological mechanisms by which nicotine mediates different types of anxiety. European Journal of Pharmacology 393, 231-236.
56. File, S.E.; Kenny, P.J. Ouagazzal Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behavioral Neuroscience 1988, 112, 1423-1429.
57. Flores, C.M.; Rogers, S.W.; Pabreza, L.A.; Wolfe, B.B.; Kellar, K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Molecular Pharmacology 1992, 41, 31-37.
58. 3 H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal. Journal of Neurochemistry 1986, 47, 1948-1954.
59. Foulds, J.; Stapleton, J.A.; Bell, N.; Swettenham, J.; Jarvis, M.J.; Russell, M.A.H. Mood and physiological effects of subcutaneous nicotine in smokers and never-smokers. Drug Alcohol Depend 1997, 44, 105-115.
60. Fowler, J.S.; Volkow, N.D.; Wang, G.J.; Pappas, N.; Logan, J.; MacGregor, R.; Alexoff, D.; Shea, C.; Schyler, D.; Wolf A. P.; Warner, D.; Zezulkova, I.; Cilento, R. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996, 379, 733-736.
61. Freedman, R.; Adler, L.E.; Bickford, P.; Byerley, W.; Coon, H.; Cullum, C.M. Schizophrenia and nicotinic receptors. Harvard Review of Psychiatry 1994, 2, 179-92.
62. Freedman, R.; Coon, H.; Myles-Worsley, M.; Orr-Urtreger, A.; Olincy, A.; Davis, A. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences 1997, 94, 587-592.
63. Freedman, R.; Hall, M.; Adler, L.E.; Leonard, S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995, 38, 22-33.
64. Freedman, R.; Wetmore, C.; Stromberg, I.; Leonard, S.; Olson, L. alpha-Bungarotoxin binding to hippocampal interneurons - immunocytochemical characterization and effects on growth factor expression. J. Neurosci 1993, 13, 1965-1975.
65. Friedman, L.; Jesberger, J.A.; Melzer, H.Y. A model of smooth pursuit performance illustrates the relationship between gain, catch-up saccade rate, and catch-up saccades amplitude in normal controls and patients with schizophrenia. Biological Psychiatry 1991, 30, 537-556.
66. Friedman, L.; Jesberger, J.A.; Melzer, H.Y. Effects of typical antipsychotic medication and clozapine on smooth pursuit performance in patients with schizophrenia. Psychiatry Research 1992, 41, 25-36.
67. Garrido, R.; Malecki, A.; Hennig, B.; and Toborek, M. Nicotine attenuates arachidonic acid-induced neurotoxicity in cultured spinal cord neurons. Brain Research. 2000, 861, 59-68.
68. Garrido, R.; Mattson, M.P.; Hennig, B.; Toborek, M. Nicotine protects against arachidonic acid induced caspase activation, cytochrome c release and apoptosis of cultured spinal cord neurons. Journal of Neurochemistry 2001, 76, 1-10.
69. George, T.; Vessicchio, J.; Sahady, D.; Head, C.; Termine, A.; Bregartner, T.; Kosten, T.; and Wexler, B. Effects of smoking abstinence on cognitive function in schizophrenia. Biological Psychiatry 2001, 49, 5S.
70. George, T.P.; Zeidonis, D.M.; Feingold, A.; Pepper, W.T.; Satterburg, C.A.; Winkel, J. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. American Journal of Psychiatry 2000, 157, 1835-1842.
71. George, T.P.; Sernyak, M.J.; Ziedonis, D.M.; Woods, S.W. Effects of clozapine on smoking in chronic schizophrenic outpatients. Journal of Clinical Psychiatry 1995, 56, 344-346.
72. Glassman, A.H.; Helzer, J.E.; Covey, L.S.; Cottler, L.B.; Stetner, F.; Tipp, J.E.; Johnson, J. Smoking, smoking cessation, and major depression. J Am. Med. Ass. 1990, 264, 1546-1549.
73. Glassman, A.H.; Jackson, W.K.; Walsh, B.T.; Roose, S.P.; Rosenfeld, B. Cigarette craving, smoking withdrawal, and clonidine. Science 1984, 226, 864-866.
74. Glassman, A.H.; Stetner, F.; Walsh, B.T. Heavy smokers, smoking cessation, and clonidine: results of a double blind, randomized trial. Journal of American Medical Association 1988, 259, 2863-2866.
75. Glassman, A.H. Cigarette smoking: implications for psychiatric illness. American Journal of Psychiatry 1993, 150, 546-553.
76. Glassman, A.H.; Covey, L.S.; Dalack, G.W.; Stetner, F.; Rivelli, S.K.; Fleiss, J.; Cooper, T. B. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clinical Pharmacology and Therapeutics 1993, 54, 670-679.
77. Goff, D.C.; Henderson, D.C.; Amico, E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 1992, 149, 1189-1194.
78. Gray, J.A.; Feldon, J.; Rawlins, J.N.P.; Hemsley, D.R.; Smith, A.D. The neuropsychology of schizophrenia. Behavioral and Brain Sciences 1991, 14, 1-84.
79. Gray, R.; Rajan, A.S.; Radcliffe, K.A.; Yakehiro, M.; Dani, J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996, 383, 713-716.
80. Greenhoff, J.; Aston-Jones, G.; Svensson, T. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiologica. Scandinavica 1986, 128, 351-358.
81. Grove, W.M.; Clementz, B.A.; Jacono, W.G.; Katsanis, J. Smooth pursuit ocular motor dysfunction in schizophrenia: evidence for a major gene. American Journal of Psychiatry 1992, 149, 1362-1368.
82. Hall, R.G.; Duhamel, Mc. Clanahan, R.; Miles, G.; Nason, C.; Rosen, S.; Schiller, P.; Tao-Yonenaga, L.; Hall, S. M. Level of functioning, severity of illness, and smoking status among chronic psychiatric patients. Journal of Nervous and Mental Disease 1995, 183, 468-471.
83. Hamera, E.; Schneider, J.; Deviney, S. Alcohol, cannabis, nicotine and caffeine use and symptom distress in schizophrenia. Journal of Nervous & Mental Disease 1995, 183, 559-565.
84. Hao, H.; Young, D.; Wei, H. Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms. Br. J. Addict. 1988, 83, 1221-1226.
85. Heishman, S. J.; Henningfield, J. E. Tolerance to repeated nicotine administration on performance, subjective, and physiological responses in nonsmokers. Psychopharmacology 2000, 152, 321-333.
86. Heishman, S.J.; Taylor, R.C.; Henningfeld, J.E. Nicotine and smoking: A review of effects on human performance. Experimental & Clinical Psychopharmacology 1994, 2, 345-395.
87. Holzman, P.S. Recent studies of pathophysiology in schizophrenia. Schizophrenia Bulletin 1987, 13, 49-75.
88. Holzman, P.S.; Solomon, C.M.; Levin, S.; Waternaux, C.S. Pursuit movement dysfunctions in schizophrenia. Archives of General Psychiatry 1984, 41, 136-139.
89. Horti, A.; Scheffel, U.; Stathis, M.; Finley, P.; Ravert, H. T.; London, E. D.; Dannals, R. F. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. J Nucl Med. 1997, 38, 1260-1265.
90. Hughes, J.R.; Hatsukami, D.K.; Mitchell, J.E.; Dahlgren, L.A. Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry 1986, 143, 993-997.
91. Hurt, R.D.; Sachs, D.P.; Glover, E.D.; Offord, K.P.; Johnston, J.A.; Dale, L.C.; Khayrallah, M.A.; Schroeder, D.R.; Glover, P.N.; Sullivan, C.R.; Croghan, I.T.; Sullivan, P.M. A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine 1997, 337, 1195-1202.
92. Imperato, A.; Mulas, A.; Di Chiara, G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. European Journal of Pharmacolgy 1986, 132, 337-338.
93. Itoh, A.; Nitta, A.; Nadai, M.; Nishimura, K.; Hirose, M.; Hasegawa, T.; and Nabeshima, T. Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid protein-infused rats. J Neurochem 1996, 66, 1113-1117.
94. Jacobs, B.L.; Asher, R.; Dement, W.C. Electrophysiological and behavioral effects of electrical stimulation of the raphe nuclei in the cat. Physiology & Behavior 1973, 11, 489.
95. Jann, M.W.; Saklad, S.R.; Ereshefsky, L.; Richards, A.L.; Harrington, C.A.; Davis, C.M. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology 1986, 90, 468-470.
96. Johnson, J.G.; Cohen, P.; Pine, D.S.; Klein, D.F.; Kasen, S.; Brook, J. Association between cigarette smoking and anxiety disorders during adolescence and early adulthood. JAMA 2000, 284, 1-4.
97. Jones, G. M. M.; Sahakian, B. J.; Levy, R.; Warburton, D. M.; Gray, J. A. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 1992, 108, 485-494.
98. Jorenby, D.E.; Leischow, S.J.; Nides, M.A.; Rennard, S.I.; Johnston, J.A.; Hughes, A.R.; Smith, S.S.; Muramoto, M.L.; Daughton, D.M.; Doan, K.; Fiore, M.C.; Baker, T.B. A controlled trial of sustained-release bupropion, a nicotinic patch, or both for smoking cessation. New England Journal of Medicine 1999, 340, 685-691.
99. Joseph, A.M.; Norman, S.M.; Ferry, L.H.; Prochazka, A.V.; Westman, E.C.; Steele, B.G.; Sherman, S.E.; Cleveland, M.; Antonnucio, D.O.; Hartman, N.; McGovern, P.G. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996, 335, 1792-1798.
100. Kandel, D.; Chen, K.; Warner, L.A.; Kessler, R.C.; Grant, B. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the US population. Drug Alcohol Depend 1997, 44, 11-29.
101. Kaneko, S.; Maeda, T.; Kume, T.; Kochiyama, H.; Akaike, A.; Shimohama, S.; Kimura, J. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha(7)-neuronal receptors and neuronal CNS receptors. Brain Res 1997, 765, 135-140.
102. Katayama, S.; Hirata, K.; Tanaka, H.; Yamazaki, K.; Fujikane, M.; Ichimaru, Y. Efficacy of transdermal nicotine in dementia: a study using event-related potentials and a middle latency response. In Domino, EF, editor. Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, MI: Npp Books, pp 1995, 289-302.
103. Kellar, K. J.; Whitehouse, P. J.; Martino-Barrows, A. M.; Marcus, K.; and Price, D. L. Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease. Brain Res 1987, 436, 62-68.
104. Kelton, M.C.; Kahn, H.J.; Conrath, C.L.; Newhouse, P.A. The effects of nicotine on Parkinson's disease. Brain and Cognition 2000, 43, 274-282.
105. Kihara T.; Shimohama, S.; Sawada, H.; Honda, K.; Nakamizo, T.; Shibasaki, H.; Kume, T.; Akaike, A. α7 Nicotinic receptor transduces signals to phosphatidylinositol-3-kinase to block Aβ amyloid-induced neurotoxicity. Journal of Biological Chemistry 2001, 276, 13541-13546.
106. Kihara, T.; Shimohama, S.; Sawada, H.; Kimura, J.; Kume, T.; Kochiyama, H.; Maeda, T.; and Akaike, A. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 1997, 42, 159-163.
107. Kihara, T.; Shimohama, S.; Urushitani, M.; Sawada, H.; Kimura, J.; Kume, T.; Maeda, T.; Akaike, A. Stimulation of alpha 4 beta 2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 1998, 792, 331-334.
108. Kirch, D.G. Nicotine and major mental disorders. In Piasecki, M, Newhouse, P, editors. Nicotine in Psychiatry: Psychopathology and Emerging Therapeutics 2000 Washington, DC: American Psychiatric Press, Inc.
109. Kirch, D.G.; Gerhardt, G.A.; Shelton, R.C.; Freedman, R.; Wyatt, R.J. Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clinical Neuropharmacology 1987, 10, 376-383.
110. Ksir, C.; Hakan, R.L.; Kellar, K.J. Chronic nicotine and locomotor activity: influences of exposure dose and test dose. Psychopharmacology 1987, 92, 25-29.
111. Lambert, N.M.; Hartsough, C.S. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. Journal of Learning Disabilities 1998, 31, 533-44.
112. Le, W.D.; Colom, L.V.; Xie, W.J.; Smith, R.G.; Alexianduand, M.; Appel, S.H. Cell death induced by beta-amyloid 1-40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis. Brain Research 1995, 49-60.
113. Lee, P.N. Smoking and Alzheimer's disease: a review of the available evidence. Neuroepidemiology 1994, 13, 131-144.
114. Leonard, S.; Adams, C.; Breese, C.R.; Adler, L.E.; Bickford, P.; Byerley, W.; Coon, H.; Griffith, J.M.; Miller, C.; Myles-Worsley, M.; Nagamoto, H.T.; Rollins, Y.; Stevens, K.E.; Waldo, M.; Freedman, R. Nicotinic receptor function in schizophrenia. Schizophrenia Bull 1996, 22, 431-445.
115. Leonard, S.; Gault, J.; Hopkins, J.; Logel, J.; Vianzon, R.; Drebing, C.; Short, M.; Walton, K.; Berger, R.; Ross, R.; Olincy, A.; Adler, L.; Freedman, R. DNA variants in the alpha 7 nicotinic receptor gene promotor are associated with schizophrenia. Biological Psychiatry 2001, 49, 166s.
116. Levin, E. D. Nicotinic systems and cognitive function. Psychopharmacology 1992, 108, 417-431.
117. Levin, E.D. The Role of Nicotinic Acetylcholine Receptors in Cognitive Function Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors. Heidelberg, Germany: Springer-Verlag, pp 2000, 587-602.
118. Levin, E.D.; Conners, C.K.; Sparrow, E.; Hinton, S.; Meck, W.H.; Rose, J.E.; March, J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 1996, 123, 55-63.
119. Levin, E.D.; Simon, B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998, 138, 217-230.
120. Levin, E.; Wilson, W.; Rose, J.; McEvoy, J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15, 429-436.
121. Levin, Edward D. Nicotinic systems and cognitive function. Psychopharmacology 1992, 108, 417-431.
122. Levy, D.L.; Holzman, P.S.; Matthysse, S.; Mendell, N.R. Eye tracking dysfunction and schizophrenia: A critical perspective. Schizophrenia Research 1993, 19, 461-536.
123. Levy, D.L.; Yasillo, N.J.; Dorus, E.; Shaughnessy, R.; Gibbons, R.D.; Peterson, J. et al Relatives of unipolar and bipolar patients have normal pursuit. Psychiatry Research 1983, 10, 285-293.
124. Lindstrom, J. The structure of Neuronal nicotinic receptors Handbook of Experimental Pharmacology. Berlin: Springer-Verlag, pp 2000, 101-162.
125. Litman, R.E.; Hommer, D.W.; Radant, A.; Clem, T.; Pickar, D. Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. Schizophrenia Research 1994, 12, 107-120.
126. Lukas, R.J. Neuronal Nicotinic Acetylcholine Receptors The Nicotinic Acetylcholine Receptor: Current Views and Future Trends. Berlin: Springer-Verlag, pp 1998, 145-173.
127. Luntz-Leybman, V.; Bickford, P.C.; Freedman, R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res 1992, 587, 130-136.
128. Luntz-Leybman, V.; Freund, R.K.; Collins, A.C. 5α-pregnan-3α-ol-20-one blocks nicotine-induced seizures and enhances paired-pulse inhibition. European Journal of Pharmacology 1985, 1990, 239-242.
129. Mancuso, G.; Warburton, D.M.; Melen, M.; Sherwood, N.; Tirelli E. Selective effects of nicotine on attentional processes. Psychopharmacology 1999, 146, 199-204.
130. Markou, A.; Kosten, T.R.; Koob, G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998, 18, 135-174.
131. Marshall, J.; Schnieden, H. Effect of adrenaline, noradrenaline, atropine, and nicotine on some types of human tremor. Journal of Neurology, Neurosurgery, and Psychiatry 1966, 29, 214-218.
132. Martin-Ruiz, C.M.; Court, J.A.; Molnar, E.; Lee, M.; Gotti, C.; Mamalaki, A. Alpha 4 but not alpha 3 and alpha 7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999, 73, 1635-1640.
133. McConville, B.J.; Sanberg, P.R.; Fogelson, M.; King, J.; Cirino, P.; Parker, K.W.; Norman, A.B. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biological Psychiatry 1992, 31, 832-840.
134. McEvoy, J.; Freudenreich, O.; McGee, M.; VanderZwaag, C.; Levin, E.; Rose, J. Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry 1995a, 37, 550-552.
135. McEvoy, J.P.; Freudenreich, O.; Levin, E.D.; Rose, J.E. Haloperidol increases smoking in patients with schizophrenia. Psychopharma-cology 1995, 119, 124-126.
136. McGehee, D.S.; Role, L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann. Rev. Physiol 1995, 57, 521-546.
137. Menza, M.A.; Grossman, N.; Van Horn, M.; Cody, R.; Forman, N. Smoking and movement disorders in psychiatric patients. Biological Psychiatry 1991, 30, 109-115.
138. Menzaghi, F.; Whelan, K.T.; Risbrough, V.B.; Rao, T.S.; Lloyd, G. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. Journal of Pharmacology and Experimental Therapeutics 1997, 280, 393-401.
139. Mereu, G.; Yoon, K.P.; Boi, V.; Gessa, G.L.; Naes, Westfall, T.C. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. European Journal of Pharmacology 1987, 141, 395-399.
140. Mihailescu, S.; PalomeroRivero, M.; MeadeHuerta, P.; MazaFlores, A.; DruckerColin, R. Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol 1998, 360, 31-36.
141. Milberger, S.; Beiderman, J.; Faraone, S.V.; Chen, L.; Jones, J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36, 37-44.
142. Mitsuoka, T.; Kaseda, Y.; Yamashita, H.; Kohriyama, T.; Kawakami, H.; Nakamura, S.; Yamamura, Y. Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism. Hiroshima Journal of Medical Sciences 2002, 51, 33-9.
143. Molina, P.E.; Ding, Y.S.; Carroll, F.I.; Liang, F.; Volkow, N.D.; Pappas, N.; Kuhar, M.; Abumrad, N.; Gatley, S.J.; Fowler, J.S. Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. Nuclear Medical Biology 1997, 24, 743-747.
144. Moll, H. The treatment of post encephalitic Parkinsonism by nicotine. British Medical Journal 1926, 1, 1079-1081.
145. Morens, D.M.; Grandinetti, A.; Reed, D.; White, L.R.; Ross, G.W. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995, 45, 1041-1051.
146. Musachio, J. L.; Villemagne, V. L.; Scheffel, U.; Stathis, M.; Finley, P.; Horti, A.; London, E. D.; Dannals, R. F. [I-125/123]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. Synapse 1997, 26, 392-399.
147. Nagamoto, H. T.; Adler, L. E.; Hea, R. A.; Griffith, J. M.; McRae, K. A.; Freedman, R. Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biological Psychiatry 1996, 40, 181-188.
148. Newhouse, P.A.; Potter, A.; Kelton, M.; Corwin, J. Nicotinic treatment of Alzheimer's disease. Biological Psychiatry 2001, 49, 268-278.
149. Newhouse, P.A.; Potter, A.; Lenox, R. The effects of nicotinic agents on human cognition: Possible therapeutic applications in Alzheimer's and Parkinson's diseases. Medicinal Chemistry Research 1993, 2, 628-642.
150. Newhouse, P.A.; Potter, A.; Levin, E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases: Implications for therapeutics. Drug Aging 1997, 11, 206-228.
151. Newhouse, P.A.; Sunderland, T.; Tariot, P.N.; Blumhardt, C.L.; Weingartner, H.; Mellow, A. Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology 1988, 95, 171-175.
152. Nigg, J.T. On inhibition/disinhibition in developmental psychopathology: views from cognitive and personality psychology and a working inhibition taxonomy. Psychological Bulletin 2000, 126, 220-246.
153. Nilsson, A.; Waller, L.; Rosengren, A.; Adlerberth, A.; Wilhelmsen, L.; Cigarette smoking is associated with abnormal involuntary movements in the general male population - A study of men born in 1933. Biol. Psychiatry 1997, 41, 717-723.
154. Nordberg, A. Clinical studies in Alzheimer patients with positron emission tomography. Behav. Brain Res. 1993, 57, 215-224.
155. Nordberg, A. Imaging of nicotinic receptors in human brain. In Domino, EF, editor. Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, M.I: Npp Books, pp 1995, 45-57.
156. Nordberg, A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biological Psychiatry 2001, 49, 200-10.
157. Nordberg, A.; Hellstrom-Lindahl, E.; Lee, M.; Johnson, M.; Mousavi, M.; Hall, R.; Perry, E.; Bednar, I.; Court, J. Chronic nicotine treatment reduces β-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). Journal of Neurochemistry 2002, 81, 655-658.
158. Nordberg, A.; Winblad, B. Reduced number of [3H] nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neuroscience Letters 1986, 72, 115-119.
159. Olincy, A.; Ross, R.G.; Harris, J.G.; Young, D.A.; McAndrews, M.A.; Cawthra, E.; McRae, K.A.; Sullivan, B.; Adler, L.E.; Freedman, R. The P50 auditory event-evoked potential in adult attention-deficit disorder: comparison with schizophrenia. Biological Psychiatry 2000, 47, 969-77.
160. Olincy, A.; Ross, R.G.; Young, D.A.; Roath, M.; Freedman, R. Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 1998, 18, 175-185.
161. Paterson, D.; Nordberg, A. Neuronal nicotinic receptors in the human brain. Progress in Neurobiology 2000, 61, 75-111.
162. Patton, G.C.; Hilbert, M.; Rosier, M.J.; Carlin, J.B.; Caust, J.; Bowers, G. Is smoking associated with depression and anxiety in teenagers? American Journal of Public Health 1996, 86, 225-230.
163. Pauly, J.R.; Marks, M.J.; Gross, S.D.; Collins, A.C. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. Journal of Pharmacology & Experimental Therapeutics 1991, 258, 1127-1136.
164. Perry, E. Cholinergic signaling in Alzheimer Disease: Therapeutic strategies. Alzheimer Disease and Associated Disorders 1995, 9, 1-2.
165. Perry, E.; Martin-Ruiz, C.; Lee, M.; Griffiths, M.; Johnson, M.; Piggott, M.; Haroutunian, V.; Buxbaum, J.D.; Nasland, J.; Davis, K.; Gotti, C.; Clementi, F.; Tzartos, S.; Cohen, O.; Soreq, H.; Jaros, E.; Perry, R.; Mckeith, I.; Court, J. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. European Journal of Pharmacology 2000, 393, 215-22.
166. Perry, E.K.; Cortical neurotransmitter chemistry in Alzheimer's disease. In Meltzer, HY, editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987, pp 887-895.
167. Perry, E.K.; Curtis, M.; Dick, D.J.; Candy, J.M.; Atack, J.R.; Bloxham, C.A.; Blessed, G.; Fairbairn, A.; Tomlinson, B.E.; Perry, R.H. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 1985, 48, 413-421.
168. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. Journal of Neuroscience 2001, 21
169. Picciotto, M.R.; Caldarone, B.J.; King, S.L.; Zachariou, V. Nicotine receptors in the brain: links between molecular biology and behavior. Neuropsychopharmacology 2000, 22, 451-465.
170. Pickworth, W.B.; Bunker, E.B.; Henningfield, J.E Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology 1994, 115, 9-14.
171. Pohl, R.; Yeragani, V.K.; Balon, R.; Lycaki, H.; Mcbride, R. Smoking in patients with panic disorder. Psychiatry Res 1992, 43, 253-262.
172. Pomerleau, O.F. Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacology Bulletin 1986, 22, 865-869.
173. Pomerleau, O.F.; Downey, K.K.; Stelson, F.W.; Pomerleau, C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. Journal of Substance Abuse 1995, 7, 373-8.
174. Potter, A.; Corwin, J.; Lang, J.; Piasecki, M.; Lenox, R.; Newhouse, P. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology 1999, 142, 334-342.
175. Prendergast, M. A.; Harris, B. R.; Mayer, S.; Holley, R. C.; Pauly, J. R. and Littleton, J. M. Nicotine exposure reduces N-methyl-D-aspartate toxicity in the hippocampus: relation to distribution of the alpha7 nicotinic acetylcholine receptor subunit. Medical Science Monitor 2001, 7, 1153-60.
176. Prochazka, A.V.; Weaver, M.J.; Keller, R.T.; Fryer, G.E.; Licari, P.A.; Lofaso, D. A randomized trial of nortriptyline for smoking cessation. Archives of Internal Medicine 1998, 158, 2035-2039.
177. Provost, S.C.; Woodward, R. Effects of nicotine gum on repeated administration of the Stroop test. Psychopharmacology 1991, 104, 536-540.
178. Quay, H.C. Inhibition and attention deficit hyperactivity disorder. Journal of Abnormal Child Psychology 1997, 25, 7-13.
179. Quik, M, Kulak, JM Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002, 23, 581-94.
180. Radant, A.D.; Hommer, D.W. A quantitative analysis of saccades and smooth pursuit during visual pursuit tracking: A comparison of schizophrenics with normals and substance abusing controls. Schizophrenia Research 1992, 6, 225-235.
181. Rasmussen, K.; Czachura, J.F. Nicotine withdrawal leads to increased firing rates of midbrain dopamine neurons. Neuroreport 1995, 7, 329-332.
182. Rezwani, A.; Levin, E. Cognitive effects of nicotine. Biological Psychiatry 2001, 49, 258-267.
183. Ross, R.G.; Hommer, D.; Radant, A.; Roath, M.; Freedman, R. Early expression of smooth pursuit eye movement abnormalities in children of schizophrenic parents. Journal of the American Academy of Child and Adolescenct Psychiatry 1996, 35, 941-949.
184. Ross, S.A.; Wong, J.Y.; Clifford, J.J.; Kinsella, A.; Massalas, J.S.; Horne, M.K.; Scheffer, I.E.; Kola, I.; Waddington, J.L.; Berkovic, S.F.; Drago, J. Phenotype characterization of an alpha4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. Journal of Neuroscience 2000, 20, 6431-6441.
185. Ruberg, M.; Ploska, F.; Javoy-Agid, F. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Research 1982, 232, 129-139.
186. Rusted, J.; Graupner, L.; O'Connell, N.; Nicholls, C. Does nicotine improve cognitive function? Psychopharmacology 1994, 115, 547-549.
187. Sacaan, A.I.; Reid, R.T.; Santori, E.M.; Adams, P.; Correa, L.D.; Mahaffy, L.S.; Bleicher, L.; Cosford, N.D.; Stauderman, K.A.; McDonald, I.A.; Rao, T.S.; Lloyd, G.K. Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist. Journal of Pharmacology and Experimental Therapeutics 1997, 280, 373-383.
188. Sahakian, B.J.; Jones, G.M.M. The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In Adlkofer, F, Thruau, K, editors. Effects of Nicotine on Biological Systems. Basel: Birkhauser Verlag, pp 1991a, 623-230.
189. Sahakian, B.J.; Jones, G.M.M. The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In Adlkofer, F, Thruau, K, editors. Effects of Nicotine on Biological Systems. Basel: Birkhauser Verlag, pp 1991b, 623-230.
190. Salin-Pascual, R.J.; Drucker-Colin, R.A. novel effect of nicotine on mood and sleep in major depression. Neuroreport 1998, 9, 57-60.
191. Sanberg, P.R.; McConville, B.J.; Fogelson, M. H.; and Norman, A. B. Nicotine potentiates neuroleptic response in animals and in Tourette's syndrome 1989, 39.
192. Saykin, A.; Gur, R.C.; Gur, R.E.; Mozley, D.; Mozley, L.H.; Resnick, S.M.; Kester, D.B.; Stafiniak, P. Neuropsychological functioning in schizophrenia: selective impairment in memory and learning. Archives of General Psychiatry 1991, 48, 618-624.
193. Saykin, A.; Schatasel, D.; Gur, R.; Kester, B.; Mozley, L. Neuropsychological deficits in neuroleptic naive patients with first-episode of schizophrenia. Archives of General Psychiatry 1994, 51, 124-131.
194. Schachar, R.; Logan, G.D. Impulsivity and inhibitory control in normal development and childhood psychopathology. Developmental Psychology 1990, 26, 710-720.
195. Schachar, R.; Tannock, R.; Logan, G. Inhibitory control, impulsiveness, and attention deficit hyperactivity disorder. Clinical Psychology Review 1993, 721-739.
196. Schneider, J.; Van Velson, M.; Menzaghi, F.; Lloyd, G. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Annals of Neurology 1998, 43, 311-317.
197. Schroder, H.; Giacobini, E.; Wevers, A.; Birtsch, A.; Schutz, U. Nicotinic receptors in Alzheimer's disease. In Domino, EF, editor. Brain Imaging of Nicotine and Tobacco Smoking. Ann Arbor, MI Npp Books, 1995, pp 73-93.
198. Schwartz, J.L.; Dubitsky, M. One-year follow-up results of a smoking cessation program. Canadian Journal of Public Health 1968, 59, 161-165.
199. Schwartz, R.D.; Kellar, K.J. Nicotinic cholinergic binding sites in the brain: In vivo regulation. Science 1983, 220, 214-216.
200. 3H]-acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J. Neurochem. 1985, 45, 427-433.
201. 3H]acetylcholine on catecholamine and serotonin axons in brain. Journal of Neurochemistry 1984, 42, 1495-1498.
202. Sellers, E.M.; Naranjo, C.; Kadlec, K. Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy smokers. Journal of Cllinical Psychopharmacology 1987, 7, 417-420.
203. Sershen, H.; Hashim, A.; Lajtha, A. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Pharmacology Biochemistry and Behavior 1987, 28, 299-303.
204. Shapiro, E.; Shapiro, A.; Fulop, G. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 1989, 46, 722-730.
205. Shimohama, S.; Greenwald, D.L.; Shafron, D.H.; Akaika, A.; Maeda, T.; Kaneko, S.; Kimura, J.; Simpkins, C.E.; Day, A.L.; Meyer, E.M. Nicotinic alpha 7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 1998, 779, 214-225.
206. Shimohama, S.; Taniguchi, T.; Fujiwara, M.; Kameyama, M. Changes in nicotinic and muscarinic receptors in Alzheimer-type dementia. J. Neurochem 1986, 46, 288-293.
207. Shytle, R.; Baker, M.; Silver, A.; Reid, B.; Sanberg, P. Smoking, nicotine and movement disorders. In Piasecki, M, Newhouse, P, editors. Nicotine in Psychiatry: Emerging Trends in Psychopathology and Novel Therapeutics. Washington, D.C.: American Psychiatric Press, 2000, pp 183-202.
208. Sihver, W.; Fasth, K.J.; Horti, A.G.; Koren, A.O.; Bergstrom, M.; Lu, L.; Hagberg, G.; Lundqvist, H.; Dannals, R.F.; London, E.D.; Nordberg, A.; Langstrom, B. Synthesis and characterization of binding of 5-[76BR]Bromo-3-[[2(S)-azetidinyl]methoxy]pyridine, a novel nicotinic acetylcholine receptor ligand, in rat brain. Journal of Neurochemistry 1999, 73, 1264-1272.
209. Silver, A.A.; Shytle, R.D.; Philipp, M.K.; Sanberg, P.R. Transdermal nicotine in Tourette's syndrome. In Clarke, PBS, Quik, M, Thurau, K, editors. The Effects of Nicotine on Biological Systems II: Birkhauser Publishers,. 1995, pp 293-299.
210. Silver, A.A.; Shytle, R.D.; Philipp, M.K.; Wilkinson, B.J.; McConville, B.; Sanberg, P.R. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. Journal of Clinical Psychiatry 2001, 62, 707-14.
211. Silver, A.A.; Shytle, R.D.; Sanberg P. R. Mecamylamine in Tourette's syndrome: a two-year retrospective case study. Journal of Child and Adolescent Psychopharmacology 2000, 10, 59-68.
212. Smith, R.C.; Singh, A.; Infante, M.; Khandat, A.; Kloos, A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2001, 27, 479-497.
213. Snaedal, J.; Johannesson, T.; Jonsson, J.E.; Gylfadottir, G. The effects of nicotine in dermal plaster on cognitive functions in patients with Alzheimer's disease. Dementia 1996, 7, 47-52.
214. Stage, K.B.; Glassman, A.H.; Covey, L.S. Depression after smoking cessation: case reports. Journal of Clinical Psychiatry 1996, 57, 467-469.
215. Stevens, K.; Kem, W.R.; Manhor, V.M.; Freedman, R. Selective alpha-7 nicotinic agonist normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl.) 1998, 136, 320-327.
216. Tidey, J.W.; O'Neill, S.C.; Higgins, S.T. d-amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology 2000, 153, 85-92.
217. Tyas, S.L. Are tobacco and alcohol use related to Alzheimer's disease? A critical assessment of the evidence and its implications. Addiction Biology 1996, 1, 237-254.
218. van der Meere, J.; Gunning, B.; Stemerdink, N. The effect of methylphenidate and clonidine on response inhibition and state regulation in children with ADHD. Journal of Child Psychology and Psychiatry and Allied Disciplines 1999, 40, 291-8.
219. van Duijn, C.M.; de Knijff, P.; Wehnert, A.; De Voecht, J.; Bronzova, J.B.; Havekes, L.M.; Hofman, A.; Van Broeckhoven, C. The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced surviva. Annals of Neurology 1995, 37, 605-610.
220. Vazquez, J.; Guzman-Marin, R.; Salin-Pascual, R.; Drucker-Colin, R. Trans-dermal nicotine on sleep and PGO spikes. Brain Research 1996, 737, 317-320.
221. Vidal, C.; Changeaux, J.P. Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 1993, 56, 22-32.
222. Waldo, M.C.; Adler, L.E.; Leonard, S.; Olincy, A.; Ross, R.G.; Harris, J.G.; Freedman, R. Familial transmission of risk factors in the first-degree relatives of schizophrenic people. Biol Psychiat 2000, 47, 231-239.
223. 2 binds to α7 nicotinic acetylcholine receptor with high affinity. Journal of Biological Chemistry 2000, 275, 5626-5632.
224. Wang, P.N.; Wang, S.J.; Hong, C.J.; Liu, T.T.; Fuh, J.L.; Chi, C.W.; Liu, C.Y.; Liu, H.C. Risk factors for Alzheimer's disease: A case-control study. Neuroepidemiology 1997, 16, 234-240.
225. Warburton, D.M.; Arnall, C. Improvements in performance without nicotine withdrawal. Psychopharmacology 1994, 115, 539-542.
226. Warburton, D.M.; Rusted, J.M. Cholinergic control of cognitive resources. Neuropsychobiology 1993, 28, 43-6.
227. Wesnes, K.; Revell, A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 1984, 84, 5-11.
228. Wesnes, K.; Warburton, D.M. Smoking, nicotine and human performance. Pharmacology and Therapeutics 1983, 21, 189-208.
229. White, H.K.; Levin, E.D. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 1999, 143, 158-165.
230. 3H] nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's Disease: an autoradiographic study. Neurology 1988, 38.
231. Whitehouse, P.J.; Martino, A.M.; Antuono, P.G.; Lowenstein, P.R.; Coyle, J.T.; Price, D.L.; Kellar, K.J.: Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Research 1986, 371, 146-151.
232. Whitehouse, P.; Hedreen, J.; White, C. Basal forebrain neurons in dementia of Parkinson's disease. Annals of Neurology 1983, 13, 243-248.
233. Whiting, P.J.; Lindstrom, J.M. Purfication and characterization of a nicotinic acetylcholine receptor from rat brain. Proceedings of the National Academy Sciences of the United States of America 1987, 84, 595-599.
234. Wilson, A.L.; Langley, L.K.; Monley, J.; Bauer, T.; Rottunda, S.; McFalls, E.; Kovera, C.; McCarten, J.R. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995, 51, 509-514.
235. Wirshing, W. C.; Engle, J.; Levin, E.; Cummings, J. L. and Rose, J. (1989) The acute effects of smoking on tardive dyskinesia Annual Meeting of the American Psychiatric Association New Research Program and Abstracts.
236. Wolf, S.; Jones, D.; Knable, M. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 1996, 273, 1225-1227.
237. Wonnacott, S.; Irons, J.; Rapier, C.; Thorne, B.; Lunt.; G.G. Presynaptic modulation of transmitter release by nicotinic receptors. Progress in Brain Research 1989, 79, 157-63.
238. Wonnacott, S.; Soliakov, L.; Wilkie, G.; Redfern, P.; Marshall, D. Presynaptic nicotinic acetylcholine receptors in the brain. Drug Develop Res 1996, 38, 149-159.
239. Yamashita, H.; Kitayama, S.; Zhang, Y. X.; Takahashi, T.; Dohi, T. and Nakamura, S. Effect of nicotine on dopamine uptake in COS cells possessing the rat dopamine transporter and in PC12 cells. Biochem Pharmacol. 1995, 49, 742-745.
240. Yassa, R.; Lal, S.; Korpassy, A.; Ally, J. Nicotine exposure and tardive dyskinesia. Biological Psychiatry 1987, 22, 67-72.
241. Zamani, M.R.; Allen, Y.S.; Owen, G.P.; Gray, J.A. Nicotine modulates the neurotoxic effect of beta-amyloid protein((25-35)) in hippocampal cultures. Neuroreport 1997, 8, 513-517.
242. Zeidonis, D.M.; Kosten, T.R.; Glazer, W.M.; Frances, R.J. Nicotine dependence and schizophrenia. Hospital & Community Psychiatry 1994, 45, 204-206.
243. Zimmerman, M.; Coryell, W. H.; and Black, D. W. Cigarette smoking and psychiatric illness 144 th Annual Meeting of the American Psychiatric Association. Washington, DC. 1991
244. Zoli, M.; Picciotto, M.R.; Ferrari, R.; Cocchi, D.; Changeux, J.P. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. European Molecular Biology Organization Journal 1999, 18, 1235-1244.